Table 3.
Grade 3 and 4 adverse events experienced by patients. Adverse events are separated based on treatment phase
| Event | Preop. | Periop. | Postop. |
|---|---|---|---|
| Edema | 1 | ||
| Nausea/vomiting | 1 | 1 | |
| Supraventricular arrhythmia | 1 | ||
| Dehydration | 1 | ||
| Pelvic abscess | 1 | ||
| Stroke | 1 | ||
| Elevated troponin T | 1 | ||
| Hypocalcemia | 1 | ||
| Anemia | 1 | ||
| Dizziness | 1 | ||
| Memory impairment | 1 | ||
| Fatigue | 1 | ||
| Anorexia | 1 | ||
| Vaginal bleeding | 1 | ||
| Total grade 3/4 events | 1 | 1 | 10 |
| Patients w/grade 4 events | 1 | 1 | 1 |
Preop., adverse events during 3–7 days of neoadjuvant imatinib; Periop., events during surgery and/or prior to starting postoperative imatinib; Postop., events after starting adjuvant imatinib. Numbers in bold indicate grade 4 adverse events. Numbers in italic indicate grade 3 adverse events